Kraig Biocraft Laboratories Announces Early Start to Production Season with Successful Small Batch Delivery of Spider Silk
- None.
- None.
ANN ARBOR, Mich., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, today announces the early start to the production season with the successful manufacture and delivery of the most recent batch of recombinant spider silk. Silk from this production cycle was processed into finished reeled raw silk and happily received on site by the Company’s Senior management this week.
The delivery of this silk further reinforces the Company’s planned production model. With this successful effort, the Company is now accelerating its plans for the upcoming 2024 production season and beyond.
“I am very excited to have produced this small batch ahead of our upcoming field trials scheduled for this spring. This early production bodes very well for the pending trials, and indicates, to me, that we are well on track to meet our spider silk production targets for 2024,” said CEO and Founder Kim Thompson.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward-Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward-looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3655756d-01dc-4238-b00e-d096e252ee4a
FAQ
What is the latest announcement from Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB)?
Who is the CEO of Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB)?
What are the production targets for 2024 for Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB)?
Where can I find more news from Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB)?
